Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

results suggest that naproxcinod could represent a valuable treatment alternative for osteoarthritis patients," said Raymond Townsend, Professor of Medicine at the University of Pennsylvania, who advised NicOx on the design and analysis of the study. "The hypertensive side effects of COX-2 inhibitors and traditional NSAIDs are a serious medical issue and there is a clear need for a new drug with no detrimental effect on blood pressure. These ABPM data have been obtained in a relevant population of chronically treated osteoarthritis patients with many cardiovascular risk factors and clearly show a consistent beneficial effect on blood pressure for naproxcinod across the dose range, in contrast to naproxen. In addition, the use of the ABPM technique gives them considerable weight, as it is widely recognized as the gold standard method for assessing the blood pressure profile of new drugs."

The 111 study design and results

In the study, 118 patients were randomized on a 1:1 basis to receive naproxcinod or naproxen, with escalating doses every three weeks. The trial included three doses of naproxcinod (375 mg bid, 750 mg bid and a supra-therapeutic dose of 1125 mg bid), which were compared to naproxen (250, 500 and 750 mg bid). 24-hour blood pressure monitoring was conducted at baseline and at the end of each three-week dose escalation (i.e. at the end of week 3, 6 and 9), using an FDA validated, ABPM device.

The primary objective of the study was to characterize the 24-hour arterial blood pressure profile of the three doses of naproxcinod, as measured by ABPM after each dose, compared to naproxen. At all time points, naproxcinod showed a decrease in the mean 24-hour SBP and DBP from baseline in contrast to naproxen. In terms of the overall treatment effect, as an average over week 3, 6 and 9, naproxen raised SBP by 1.5 mmHg from baseline, while naproxcinod lowered it by 2.3 mmHg, resulting in a difference between the two treatments of 3.8 mmHg (p=
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Cardinal Innovations Healthcare Solutions , ... high-touch service delivery, is featuring its highly successful ... National Council for Behavioral Health,s annual National Conference ... 2015, at the Gaylord Palms Resort and Convention ... attracts participants from mental health and addiction treatment ...
(Date:4/20/2015)... 20, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... and drug-delivery therapies, today shared highlights of new ... Cancer Research (AACR) annual meeting. Halozyme also announced ... Phase 2 study in pancreatic cancer, Study 202, ... American Society of Clinical Oncology (ASCO). ...
(Date:4/20/2015)... , April 20, 2015  Published results ... trends in the ability of Neuraltus Pharmaceuticals ... of amyotrophic lateral sclerosis (ALS, also known as ... treatment period. While NP001,s slowing of decline in ... was not statistically significant, clinically meaningful slowing of ...
Breaking Medicine Technology:Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... Pursuant to the filing of a Form 13D with the ... global leader in protection solutions, today announced it has made ... acquired 9.66% of the issued and outstanding shares of common ... manufactures and sells a comprehensive line of safety garments and ...
... SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that ... its extended-release nutritional products based on the Company,s proprietary ... first significant direct retail sales of its nutritional products. ... CEO, said, "Shipment of these initial orders marks an ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products 2
(Date:4/20/2015)... Mutare Health, a Strategic Business ... Lawrence Kosinski, MD, MBA, AGAF, to serve as ... a unique combination of medical experience, technical expertise, ... Health team as it continues to develop ... of care in the healthcare environment. He is ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Goodreads is ... Health Insurance: Why It’s Good for You and Your ... Paul Zane Pilzer and Rick Lindquist have released ... Insurance: Why It’s Good for You and Your Company. ... employer health insurance woes - employer-funded individual health insurance. ...
(Date:4/20/2015)... April 20, 2015 Advance Home Care ... personal matter that many customers would prefer not to share ... March 30th a discreet delivery method allowing customers to order ... at their home without fear of a neighbor or passerby ... method is available now on all orders and no minimum ...
(Date:4/20/2015)... Florida Hospital at Connerton Long Term ... from Select Medical, during the annual ceremony hosted at ... Chief Operating Officer, Debi Martoccio, received the Leadership Award ... of six recipients out of 113 hospitals nationwide. The ... for the contributions to the community as well as ...
(Date:4/20/2015)... 1% for the Planet , one of the ... Williams, the network’s Director of Partnerships, will step into the ... been part of 1% for the Planet since early 2014, ... Northern Forest Canoe Trail, a 1% for the Planet nonprofit ... of and advocacy for the outdoors, a commitment which is ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3
... , WEDNESDAY, Jan. 5 (HealthDay News) -- Women with ... to have a gene thought to be connected to the ... help researchers gain more insight into the development of MS, ... particularly among women. Although no one knows what causes MS, ...
... Lou Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), ... clumps in brain and spinal-cord cells that include an ... building block of the lesions formed by these clumps. ... Journal of Clinical Investigation , a team led by ...
... are reporting development of a less expensive, more eco-friendly method ... may be a more healthful form of water. Their report ... Research . Changgong Meng and Feng Huang note ... mixture of H2O and tiny amounts of D2O about ...
... of researchers at the Columbia University College of Dental ... key role in vascular pathogenesis, specifically atherosclerosis, or what ... the number one cause of death in the ... in cardiovascular diseases has been challenging because researchers have ...
... maximum temperature of children,s bath water can significantly reduce ... the risk of scalding, according to researchers at The ... partnership with Glasgow Housing Association, found that families with ... and cold water pipes in their bathroom had bath ...
... New Rochelle, NY, January 5, 2011A new, simplified method ... of shuttling genes into host cells will help advance ... into large animal studies and human clinical trials. The ... an article published Instant Online ahead of publication in ...
Cached Medicine News:Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Bacteria eyed for possible role in atherosclerosis 2Health News:Bacteria eyed for possible role in atherosclerosis 3Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 2Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 3Health News:Faster, scalable method for producing AAV-based gene transfer vectors 2
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: